Novel prostaglandin receptor modulators: A patent review (2002 - 2012) - Part I: Non-EP receptor modulators

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 1, 2013, Pages 47-77

  Lamers, Christina ^a   Flesch, Daniel ^a   Schubert Zsilavecz, Manfred ^a   Merk, Daniel ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Allergy; Asthma; CRTH2 receptor; DP1 receptor; FP receptor; Glaucoma; Inflammation; IP receptor; TP receptor

Indexed keywords

3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; INTERLEUKIN 13; LAROPIPRANT; PROSTAGLANDIN F RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RAMATROBAN; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; APPLIED RESEARCH; ASTHMA; ATOPIC DERMATITIS; BINDING AFFINITY; BLADDER CONTRACTION; BONE MASS; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COVALENT BOND; CYTOKINE PRODUCTION; DRUG BINDING; DYSLIPIDEMIA; HAIR GROWTH; HUMAN; IC 50; INTRAOCULAR PRESSURE; LYMPHOCYTE DIFFERENTIATION; MELANOGENESIS; NONHUMAN; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTAGLANDIN SYNTHESIS; PULMONARY HYPERTENSION; REVIEW; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TRANSCRIPTION INITIATION; UTERUS CONTRACTION;

ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN;

EID: 84871483728     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.736495     Document Type: Review

References (154)

1. Ricciotti E, FitzGerald GA. Prostaglandins and Inflammation. Arterioscler Thromb Vasc Biol 2011;31(5):986-1000
2. Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev 2011; 63(3):471-538
3. Cathcart M, O'Byrne KJ, Reynolds JV, et al. COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta BBARev Cancer 2012;1825(1):49-63
4. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66(20):9794-7 (Pubitemid 44672027)
5. Suzuki J, Ogawa M, Watanabe R, et al. Roles of prostaglandin E2 in cardiovascular diseases. Int Heart J 2011;52(5):266-9
6. Honda T, Tokura Y, Miyachi Y, Kabashima K. Prostanoid receptors as possible targets for anti-allergic drugs: recent advances in prostanoids on allergy and immunology. Curr Drug Targets 2010;11(12):1605-13
7. Kuwano K, Hashino A, Asaki T, et al. 2- [4-[(5,6-diphenylpyrazin-2-yl) (isopropyl) amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322(3):1181-8 (Pubitemid 47295780)
8. The Procter and Gamble Co. C16 unsaturated FP-selective prostaglandins analogs. US6451859; 2002
9. The Procter and Gamble Co. Aromatic C16-C20-Substituted Tetrahydro Prostaglandins Useful AS FP Agonists. EP1012137; 2002
10. The Procter and Gamble Co. C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists. US6444840; 2002
11. The Procter and Gamble Co. C16 unsaturated FP-selective prostaglandins analogs. US200237913; 2002
12. Duke University. Aromatic C 16?-C 20?- Substituted Tetrahydro Prostaglandins Useful AS FP Agonists. EP1012136; 2004
13. Duke University. Aromatic C16-C20-Substituted Tetrahydro Prostaglandins Useful AS FP Agonists. EP1021402; 2005
14. Kyowa Hakko Kirin Co., Ltd. FP Receptor Agonist. WO20094990; 2009
15. Applied Research Systems ARS Holding N.V. Thiazolidine carbocamide derivatives as modulators of the prostaglandin F receptor. WO03082278A1; 2003
16. Polyphor AG. Conformationally Constrained, Fully Synthetic Macrocyclic Compounds. WO201114973; 2011
17. Polyphor AG. Conformationally Constrained, Fully Synthetic Macrocyclic Compounds. WO201115241; 2011
18. Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with compounds that have FP prostaglandin agonist activity to treat glaucoma and ocular hypertension. US6342524; US2002103255; US6646001; 2002
19. Alcon Manufacturing, Ltd. 11beta-fluoro 15beta-hydroxy PGF2alpha analogs as FP receptor antagonists. US6441033; 2002
20. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel prostaglandin F2alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther 1999;290(3):1278-84 (Pubitemid 29400270)
21. Allergan Sales, Inc. Glaucoma treatments with reduced hyperpigmentation. US200318078; 2003
22. The Universityof Arizona. Methods For Screening For Substances Which Inhibit FP Prostanoid Receptor. WO200258546; 2002
23. Medical Research Council. FP Receptor Antagonists Or Pgf2 Alpha Antagonista For Treating Pathological Conditions Of The Uterus. WO200389001; 2003
24. Duke University. Compositions And Methods For Promoting Nasal Patency And Treating Neurogenic Bladder Using Prostaglandins. WO2010108012A1; 2010
25. Duke University. Compositions And Methods For Inhibiting Hair Growth. WO201114649; 2011
26. Taisho Pharmaceutical Co., Ltd. Hair Growth Agent Composition. WO200723841; 2007
27. Cayman Chemical Co. Method For Screening Of Prostaglandin Compounds Comprising An Optimal Formulation For The Enhancement Of Hair Growth And The Stimulation Of Follicular Anagen And Formulations Resulting Therefrom. US200988473; 2009
28. Ursapharm Arzneimittel GmbH. Phosphate-Free Pharmaceutical Composition For The Treatment Of Glaucoma. WO2010130462; 2010
29. Wilson SM, Sheddan NA, Newton R, Glembycz MA. Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release. Mol Pharmacol 2011;79(3):586-95
30. Bayer Schering Pharma Aktiengesellschaft. Trisubstituted Furopyrimidines And The Use Thereof As Activators Of The Ip Receptor. WO200962605; 2009
31. Bayer Schering Pharma Aktiengesellschaft. Substituted Pyrrolotriazines And Their Use. US201128479; 2011
32. Arena Pharmaceuticals, Inc. Yrazolyl Substituted Carbonic Acid Derivatives As Modulators Of The Prostacyclin (PGI2) Receptor Useful For The Treatment Of Disorders Related Thereto. WO201068242A1; 2010
33. Arena Pharmaceuticals, Inc. Modulators of the Prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto. WO20100772751; 2010
34. Arena Pharmaceuticals, Inc. Modulators of the prostacylcin (PGI2) receptor useful for the treatment of disorders related therto. WO2009117095A1; 2009
35. Novartis AG. IP Receptor Agonist Heterocyclic Compounds. WO20127539; 2012
36. Syntex (USA) LLC. Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators. US6335459; 2002
37. Bayer Healthcare AG. Carboxamides Derivatives. WO2003106403; 2003
38. Bayer Aktiengesellschaft. 2-Naphtamide Derivatives. WO2003106402; 2003
39. Bayer Healthcare AG. Phenyl Or Heteroaryl Amino Alkane Derivatives As Ip Receptor Antagonist. WO200443926; 2004
40. Roche bioscience. Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists. US2002169171; 2002
41. Roche bioscience. Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists. US2002165235; 2002
42. Syntex (USA) LLC. Substituted-phenyl ketone derivatives as IP antagonists. US6335459; 2002
43. Roche Palo Alto LLC. Substituted arylamides as IP antagonists. US2004220247; 2004
44. Actelion Pharmaceuticals Ltd. Therapeutic Compositions Containing Macitentan. WO201018549; 2010
45. Actelion Pharmaceuticals Ltd. Therapeutic Compositions Containing Macitentan. US2011136818; 2011
46. The Procter and Gamble Co. Methods for identifying compounds for regulating muscle mass or function using prostanoid IP receptors. US200715214; 2007
47. Medical Research Council. Substituted Pyrrolotriazines And Their Use Ip Receptor Antagonists For The Treatment Of Pathological Uterine Conditions. WO200471508; 2004
48. Giannarelli C, Zafar MU, Badimon JJ. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism? Thromb Haemost 2010;104(5):949-54
49. Bal Dit Sollier C, Crassard I, Simoneau G, et al. Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 2009;28(5):505-13
50. Kabashima K, Murata T, Tanaka H, et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat. Immunol 2003;4(7):694-701 (Pubitemid 36874447)
51. Evolva, Inc. Treatment Of Infections With Tp Receptor Antagonists. WO2011057262A2; 2011
52. Adir Et Compagnie. Derives de 1,2,3,4- tetrahydronaphtalene, de chromanne et de thiochromanne comme agents antithrombotiques. EP0648741A1; 1993
53. The TrusteesOf The University Of Pennsylvania. Novel Tetrahydronaphthalene Antagonists To The Thromboxane A2 (TP) Receptor. WO2012015944A2; 2012
54. Thoray Industries, Inc. Benzene Fused Heterocyclic Derivatives Having Thromboxane A2 Receptor Antagonistic Activity And Prostaglandin I2 Agonistic Activity And Application Thereof. US6407096B1; 2002
55. Les Laboratoires Servier. Use Of An Anti-Atherothrombotic Compound In Obtaining Medicaments Intended For The Treatment Of Vascular Disorders. US20070238785A1; 2007
56. Musc Foundation For Research Development. Methods For The Treatment Of Cancers. WO2009089098A1; 2009
57. Thromboxane Inhibitors. Compositions and Methods of Use. US20030050305A1; 2003
58. B.M.R.A. Corp. B.V. Compositions And Methods Involving The Combination Of A Thromboxane A2 Receptor Antagonist And An Inhibitor Of Cyclooxygenase-1. WO2005016334A1; 2005
59. Astrazeneca AB. Combinations Comprising A Glucocorticoid Receptor Modulator For The Treatment Of Respiratory Diseases. WO2011061527A1; 2011
60. Astrazeneca AB. New Combinations For The Treatment Of Asthma. WO2011012897A1; 2011
61. Philip G, van Adelsberg J, Loeys T, et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol 2009;124(5):942-8; e1-9
62. Applied Research Systems Ars Holding N.V. Pyrrolidin-2-One Derivatives For Use As Dp1 Receptor Agonists. WO200661366; 2006
63. Aventis Pharmaceuticals, Inc. 2,6- Substituted-4-Monosubstituted Aminopyrimidine As Prostaglandin D2 Receptor Antagonists. WO2006044732A2; 2006
64. Aventis Pharmaceuticals, Inc. A Combination Of Niacin And A Prostaglandin D2 Receptor Antagonist. WO2008039882A1; 2008
65. Aventis Pharmaceuticals, Inc. Dihydrogen Phosphate Salt Of A Prostaglandin D2 Receptor Antagonist. US20080194600A1; 2008
66. Aventis Pharmaceuticals, Inc. Dihydrogen Phosphate Salt Of A Prostaglandin D2 Receptor Antagonist. WO2007047378A2; 2007
67. Amira Pharmaceuticals, Inc. Substituted Pyrimidines As Prostaglandin D2 Receptor Antagonists. WO2011115940A1; 2011
68. Amira Pharmaceuticals, Inc. A Substituted Pyrimidine As A Prostaglandin D2 Receptor Antagonist. WO2011115943A1; 2011
69. Aventis Pharmaceuticals, Inc. 2-Phenyl-Indoles As Prostaglandin D2 Receptor Antagonists. WO2006081343A1; 2006
70. Sanofi-Aventis. 2-Phenyl Indoles As Prostaglandin D2 Receptor Antagonists. WO2008014186A1; 2008
71. Merck Frosst Canada & Co. Dihydropyrrolo[1,2-a]indole and tetrahydropyridino[1,2-a]indole derivatives as prostaglandin D2 receptor antagonists. WO02094830A2; 2002
72. Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentaindole derivatives. WO2005056527A1; 2005
73. Merck & Co., Inc. Method Of Treating Atherosclerosis, Dyslipidemias And Related Conditions. WO2006026273A2; 2006
74. Merck & Co., Inc. Method Of Treating Pathological Blushing. WO2006052798A3; 2006
75. Merck & Co., Inc. Methods Of Treating Pathological Blushing. US20070299122A1; 2007
76. Merck & Co., Inc. Methods Of Treating Atherosclerosis, Dyslipidemias AndRelated Disorders. US20040229844A1; 2004
77. Merck & Co., Inc. Method Of Treating Atherosclerosis, Dyslipidemias And Related Conditions. WO2008097535A2; 2008
78. Merck & Co., Inc. Methods Of Treating Atherosclerosis, Dyslipidemias And Related Disorders. WO2006089309A2; 2006
79. Astellas Pharma, Inc. Thiazolylbenzofuran Derivatives As Leukotriene And Prostaglandin D2 Receptor Antagonists. WO2006046683A1; 2006
80. President And Fellows Of Harvard College. Neurodegenerative Diseases And Methods Of Modeling. US2010130574; 2010
81. Sturino CF, O'Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro- 5-(methylsulfonyl)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem 2007;50(4):794-806 (Pubitemid 46332991)
82. Hwang, Cheng Shine. Reduction Of Hair Growth. US20050112075A1; 2005
83. Institut Pasteur De Lille, Institut National De La Sante Et De La Recherche Medicale (INSERM). Use Of Active Compounds Capable Of Modulation The Intracellular Pathway Triggered By The Dp Receptor In Langerhans Cells. WO0245718A1; 2002
84. Taisho pharmaceutical Co., Ltd. Pharmaceuticals for Xerosis. US20050192357A1; 2005
85. Schuligoi R, Sturm E, Luschnig P, et al. CRTH2 and D-Type Prostanoid Receptor Antagonists as Novel Therapeutic Agents for Inflammatory Diseases. Pharmacology 2010;85(6):372-82
86. Pettipher R,Whittaker M. Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis. J. Med. Chem 2012;55(7):2915-31
87. Norman P. DP(2) receptor antagonists in development. Expert Opin Investig Drugs 2010;19(8):947-61
88. Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012;42(1):38-48
89. Ulven T, Kostenis E. Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr Top Med Chem 2006;6(13):1427-44 (Pubitemid 44144925)
90. Ulven T, Kostenis E. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin Ther Patents 2010;20(11):1505-30
91. Norman P. A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Patents 2011;21(12):1931-6
92. Norman P. Evaluation of WO2012078210 - development process for the preparation of a DP2 receptor antagonist; Ironwood's first development DP2 antagonist. Expert opin Ther Patents 2012;22(10):1257-61
93. Oxagen Ltd. Compounds Having Crth2 Antagonist Activity. WO200812511; 2008
94. Oxagen Ltd. Compounds Having CRTH2 Antagonist Activity. US201022613; 2010
95. Oxagen Ltd. Compounds Having Crth2 Antagonistic Activity. US20100063103; 2010
96. Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. WO201039982; 2010
97. Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. US2011311483; 2011
98. Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. US20110150834A1; 2011
99. Ironwood Pharmaceuticals, Inc. CRTH2 Modulators And Preparation Thereof. WO201278210; 2012
100. Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. WO20129134; 2012
101. Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. WO20129137; 2012
102. Merck Frosst Canada Ltd. Indole Derivatives As Crth2 Receptor Antagonists. WO201031182; 2010
103. Gallant M, Beaulieu C, Berthelette C, et al. Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett 2011;21(1):288-93
104. Merck Frosst Canada Ltd. Indole Derivatives As CRTH2 Receptor Antagonists. WO201031183; 2010
105. Merck Sharp Dohme Corp. Merck Frosst Canada. Indole Derivatives As CRTH2 Receptor Antagonists. WO201099039; 2010
106. Merck Frosst Canada Ltd. Azaindole Derivatives As CRTH2 Receptor Antagonists. WO201031184; 2010
107. Wyeth, LLC. Indole Based Receptor Crth2 Antagonists. US2011105509; 2011
108. Argenta Oral Therapeutics Ltd. Quinoline Derivatives Having Dp And/ Or Crth2 Receptor Activity. WO201040992; 2010
109. Argenta Oral Therapeutics Ltd. WO2010040989A1; 2010
110. F. Hoffmann-La Roche AG. Aminotetrahydroindazoloacetic Acids. US201016369; 2010
111. F. Hoffmann-La Roche AG. Aminotetrahydroindazoloacetic Acids. US201016368; 2010
112. F. Hoffmann-La Roche AG. Substituted Aminotetralines. US201041713; 2010
113. F. Hoffmann-La Roche AG. Bi-Aryl Aminotetralines. US201041714; 2010
114. F. Hoffmann-La Roche AG. Monoaryl Aminotetralines. US201041760; 2010
115. F. Hoffmann-La Roche AG. Naphthylacetic Acids. US2010125058; 2010
116. F. Hoffmann-La Roche AG. Naphthylacetic Acids. US2010125061; 2010
117. F. Hoffmann-La Roche AG. Naphthylacetic Acids. WO201055005; 2010
118. Hoffmann-La Roche AG. Naphthylacetic acids. WO2010055004A1; 2010
119. Boehringer Ingelheim International GmbH. Pyrazole Compounds As CRTH2 Antagonists. US20120028938A1; 2012
120. Boehringer Ingelheim International GmbH. Pyrazole Compounds As Crth2 Antagonists. WO2011092140A1; 2011
121. Boehringer Ingelheim International GmbH. New Pharmaceutical Compositions For Treatment Of Respiratory And Gastrointestinal Disorders. WO2010089391A1; 2010
122. Bayer Healthcare AG. Pyrimidine Derivatives Useful For The Treatment Of Diseases Mediated By CRTH2. WO2004096777A1; 2004
123. Actimis Pharmaceuticals, Inc. Particulates Of A Crth2 Antagonist. WO2008156780A1; 2008
124. Actimis Pharmaceuticals, Inc. Amine Salts Of A Crth2 Antagonist. WO2008156781A1; 2008
125. Boehringer Ingelheim International GmbH. Polymorph Of [4,6-Bis (Dimethylamino)-2-(4-{[4- (Trifluoromethyl)Benzoyl]Amino}Benzyl) Pyrimidin-5-Yl]. WO2011005645A1; 2011
126. Boehringer Ingelheim International GmbH. Pharmaceutical Composition For Treatment Of Respiratory And Inflammatory Diseases. WO2012013566A1; 2012
127. Boehringer Ingelheim International GmbH. Pharmaceutical Composition For The Treatment Of Respiratory And Inflammatory Diseases. WO2012013567A1; 2012
128. Actimis Pharmaceuticals, Inc. Isotopically Enriched Pyrimidin-5-Yl Acetic Acid Derivatives As Crth2 Antagonists. WO2010027448A1; 2010
129. Amira Pharmaceuticals, Inc. Antagonists Of Prostaglandin D2 Receptors. WO2010003120A2; 2010
130. Amira Pharmaceuticals, Inc. Heteroaryl Antagonists Of Prostaglandin D2 Receptors. WO2010039977A2; 2010
131. Amira Pharmaceuticals, Inc. Antagonists Of Prostaglandin D2 Receptors. WO2010003127A2; 2010
132. Amira Pharmaceuticals. DP2 Antagonist And Uses Thereof. WO2011085033A2; 2011
133. Amira Pharmaceuticals, Inc. Heteroalkyl Biphenyl Antagonists Of Prostaglandin D2 Receptors. WO2010042652A2; 2010
134. Amira Pharmaceuticals, Inc. DP2 Antagonist And Uses Thereof. US20110034558A1; 2011
135. Amira Pharmaceuticals, Inc. Cycloalkane [B]Azaindole Antagonists Of Prostaglandin D2 Receptors. WO2010054113A2; 2010
136. Amira Pharmaceuticals, Inc. Cycloalkane [B]Azaindole Antagonists Of Prostaglandin D2 Receptors. WO2010054114A2; 2011
137. Amira Pharmaceuticals, Inc. Cycloalkane [B]Indole Antagonists Of Prostaglandin D2 Receptors. WO2010008864A2; 2010
138. Amira Pharmaceuticals, Inc. Dermal Formulations Of Dp2 Receptor Antagonists. WO2011014588A2; 2011
139. Amira Pharmaceuticals, Inc. Ophthalmic Pharmaceutical Compositions Of Dp2 Receptor Antagonist. WO2011014587A2; 2011
140. Actelion Pharmaceuticals Ltd. 3- (HETEROARYL-AMINO)-1,2,3,4- Tetrahydro-9h-Carbazole Derivatives And Their Use As Prostaglandin D2 Receptor Modulators. WO2011117798A1; 2011
141. Shionogi & Co., Ltd. Sulfonamide Derivative Having Pgd2 Receptor Antagonistic Activity. WO2007037187A1; 2007
142. Astrazeneca AB. Novel Compounds. WO2007052023A2; 2007
143. Actelion Pharmaceuticals Ltd. 1-Phenyl-Substituted Heterocyclyl Derivatives And Their Use As Prostaglandin D2 Receptor Modulators. WO2012004722A1; 2012
144. Almirall, S.A. New Pyrazole Derivatives Having Crth2 Antagonistic Behaviour. WO201269175; 2012
145. Tricyclic Indole-Derived Spiro Derivatives As Crth2 Modulators. WO20116936; 2011
146. Merck Serono S.A. Phenoxy Acetic Acid Derivatives. WO201092043; 2010
147. Merck Sharp and Dohme Corp.; Schering Corp. Quinazolinone-Type Compounds As Crth2 Antagonists. WO201251036; 2012
148. Taisho Pharmaceutical Co., Ltd. Isoquinoline Derivative. EP2377851; 2011
149. Cara Therapeuticts, Inc. Azabenzimidazolones. WO2010045276A2; 2010
150. Array Biopharma, Inc. 7-Phenoxychroman carboxylic acid derivatives. WO2010075200A1; 2010
151. Astrazeneca AB. Combination Of A Benzoxazinone And A Further Agent For Treating Respiratory Diseases. WO2011073662A1; 2011
152. Astrazeneca AB. Pharmaceutical Product Comprising A P38 Kinase Inhibitor And A Second Active Ingredient. WO2010071583A1; 2011
153. Astrazeneca AB. Combinations Comprising A Glucocorticoid Receptor Modulator For The Treatment Of Respiratory Diseases. WO2011061527A1; 2011
154. Astrazeneca AB. Combination Comprising 6-Fluoro-N-((1s,4s)-4-(6- Fluoro-2,4-Dioxo-1-(4'-(Piperazin-1-Yl- Methyl)Biphenyl-3-Yl)-1,2- Dihydropyrido[2,3-D]Pyrimidin-3(4h)- Yl)Cyclohexyl)Imidazo[1,2-A]Pyridine-2- Carboxamide Or A Salt. WO2010004319A1; 2010